Interestingly, many pre-clinical studies show differing proliferative versus anti-proliferative effects in ERα and AR-positive breast cancer that correlates with variation in the ratio of these steroid receptors and the availability of their respective ligands (i.e., estradiol and DHT). Here, ESR1 is linked to breast cancer.